Head Diagnostics

Novel Digital Biomarker for Parkinson’s Disease

Current diagnosis of neurodegenerative diseases such as Parkinson’s disease (PD) is largely based on subjective assessments of motor symptoms observed later in the disease course. Furthermore, there is a lack of tools to accurately and quickly identify and monitor patients and track disease progression. Our novel, hand-held medical device enables the assessment of Parkinson’s disease in just three seconds. We non-invasively measure Ocular Microtremor (OMT), an intrinsic neurophysiological biomarker of brainstem function that exhibits a specific signature in PD. In addition, OMT has been validated as a biomarker for MS and stroke in over 15 publications. We are continuing validation of our device at Northumbria University, with the National Health Service (UK), and with a multi-national medical device company. Our device offers a fast, objective endpoint to affordably and frequently gather high-quality, enriched patient data to support better, more accurate decision-making in PD.

Dublin, Ireland
David van Zuydam, CEO
Mindaugus Norkus, PhD, CTO
Return to Alumni Page

More Alumni Startups